Bhat Laxminarayan 4

What Happened
Laxminarayan Bhat, President, Chief Executive Officer and a director of Reviva Pharmaceuticals Holdings, received two stock option awards on March 18, 2026 totaling 150,075 optioned shares (109,150 + 40,925). The Form 4 lists these as derivative awards (code A) with $0.00 shown as the acquisition amount (the awards were granted, not purchased). The options’ exercise price is set based on the issuer’s closing common share price on the grant date per the company’s 2020 Equity Incentive Plan.

Key Details

• Transaction date: March 18, 2026; Form 4 filed March 20, 2026 (appears timely).
• Awards: 109,150-share option and 40,925-share option = 150,075 total optioned shares. Filing shows $0.00 as acquisition amount for the grants.
• Vesting (per footnotes): 46,899 shares vest immediately (34,110 + 12,789). The remaining 103,176 shares vest in equal monthly installments from April 2026 through December 2028 (last-day-of-month vesting).
• Exercise price: Determined by the closing price on the grant date under the 2020 Plan (not shown as a cash amount on the Form 4).
• Shares owned after transaction: Not specified in the filing.
• Filing code: Award/Grant (A). No 10b5-1 plan, tax withholding, or late-filing flag noted in the Form 4.

Context
These were option grants (compensation), not open-market purchases or sales. Grants are common for executive compensation and do not by themselves indicate the insider bought or sold company stock. Because a portion vests immediately and the rest vests monthly over ~33 months, the award aligns executive incentives with future performance and retention.